If you like to see how the sausage is made, Seeking Alpha takes a look inside Geron, a company representative of the messy business of developing the latest regenerative medicine and cancer therapies: ''Geron has two telomerase-based cancer drugs in human trials, though both are early stage. For metastatic prostate cancer, the company is injecting ...

MSNBC looks at the funding situation for the California Insitute for Regenerative Medicine: ''Voters passed Proposition 71 in 2004 to create the institute and give it authority to borrow and spend $3 billion over 10 years. Lawsuits, however, have prevented it from going to the Wall Street bond market for its money. So the institute will fund the ...

The Scientist takes us inside one of a number of trials of first generation autologous stem cell therapy aimed at regenerating the damage of heart disease: ''More than 10 years ago, researchers isolated endothelial progenitor cells from the ranks of CD34+ cells derived from bone marrow or mobilized to the peripheral blood. This provided a ...

The draft strategic plan (PDF) developed by the California Institute for Regenerative Medicine (CIRM) provides another confirmation of the conventional wisdom regarding timelines for the next generation of stem cell therapies. From SignOnSanDiego.com: ''The proposed strategic plan includes five and ten year goals, and a breakdown of the money that ...